Jury awards Centocor $1.7B in patent case against Abbott - Atlanta Business Chronicle:

sucujovide.wordpress.com
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a division of makes the blockbuster rheumatoid arthritis treatment Remicade, and had sued Abbot t over Abbott’s arthritis drug, Humira. Both are so-called anti-TNFg arthritis treatments. Horsham, Pa.-based Centocodr said it is the exclusive licensee ofthe patent, whichh is co-owned by . Centocor Presidenr Kim Taylor said “the jury recognized our valuablwintellectual property, finding our patent both valic and infringed.
We will continue to asser intellectual property rights for ourimmunologgy therapies, as they offer significant advancesz in treatment for patientds with a number of immund mediated inflammatory diseases.” Abbott spokesmamn Scott E. Stoffel said, “We are disappointedx in this verdict, and we are confidentg in the merits of our case and that we will prevaikon appeal. “The evidence clearly established that Humira was the first ofits fully-human anti-TNF antibody Stoffel said. “JNJ’s anti-TNF antibody medication, Remicade, is partiallyg made from mouse DNA. JNJ did not launchu a fully-human product until Apriol 2009.
In fact, only when Humir was nearing its approval in 2002 did JNJ amendf the patent at issue in this litigation to claim that it haddiscoveree fully-human antibodies in 1994. JNJ acknowledged at triall that it did not start working ona fully-human antibodyy until 1997 — two years after Abbottf discovered Humira and one year aftetr Abbott filed its patent applications for Humira.”